Lek Anti-Infectives Lendava celebrates 30th anniversary of potassium clavulanate production
- Potassium clavulanate remains the flagship of Lek's production plant in Lendava, and the company is reaching new milestones with it year after year.
- Lek's Lendava site is one of the key parts of Sandoz, which is one of the few global manufacturers to keep antibiotic production on European soil.
- The good work of our associates in Lendava is supported by many investments. The total investment in the site over the years is EUR 150 million.
Professionalism, quality, knowledge, a long tradition and involvement in the local environment are words that can be used to describe the three proud decades of Lek's Anti-Infectives Lendava site. In 1992, production began of potassium clavulanate, the active ingredient in Sandoz's best-selling broad-spectrum antibiotic, Amoxiclav. The anniversary was celebrated at the Lendava site together with the associates and in the presence of former directors.
The Lendava site dates back to 1982, when a small plant, then producing cosmetics, marked the beginning of its development. The production of active pharmaceutical ingredients in Lendava began in 1985, but an important turning point came in the early 1990s, when a modern production plant was built and production of potassium clavulanate, which is today and will continue to be a key product of the site, began. Production has been steadily increasing and accordingly Lek in Lendava has invested heavily in increasing production capacity and building the necessary facilities. Potassium clavulanate has thus triggered a continuous cycle of investment. In 1998, production was further expanded, and an important sustainable milestone and commitment to the local community was the installation of a wastewater treatment plant, co-owned with the Municipality of Lendava in 2001. In 2005, the Final Operations facility was built and in 2011, the fermentation capacity of the key ingredient of Sandoz's best-selling broad-spectrum antibiotic was increased.
In its first year of production, potassium clavulanate ranked among Lek's top 10 products and immediately became a success story. This active pharmaceutical ingredient remains the flagship of the Lendava production facility, reaching new milestones year after year.Last year alone saw record volumes, with the successful transfer of production of compounds from Prevalje and the start-up of a continuous isolation process for this key antibiotic ingredient.
"The credit for our progress goes to our dedicated team of associates. Together, with our expertise, cooperation, cohesion and flexibility, we ensure that the plant is not only increasing the volumes produced, but also improving its efficiency, thus maintaining its strong position against otherwise very tough global competition," said Saša Sankovič, Site Head of Anti-Infectives Lendava, on the occasion of the anniversary.
Committed to the present, ready for the future
Anti-infectives, including potassium clavulanate, are a major part of Sandoz's global business, which is why the company does not take antibiotics for granted, but invests in production. To date, the total investment in the Lendava site amounts to EUR 150 million, and the plant represents one of the key parts of the global pharmaceutical company and one of the few antibiotic production facilities on European soil. Half of the total volume produced is vertically integrated into the company's own production of a broad-spectrum antibiotic, and half is sold on the commercial market, in the form of a compound. The long-term success is based on a strong manufacturing heritage, and with modernization and continued investment, the Lendava site is well-equipped for the future.
Investing in the development and growth of the business also has a positive impact on the development of the local environment in which it operates. Lek is an important member of the local community in Lendava, with its two units, Solids and Anti-Infectives, providing jobs for almost 800 people, working constructively with various institutions in Lendava and the surrounding area, and operating efficiently over the years, while respecting all ecological aspects of its operations.
Novartis is the leading provider of medicines in Slovenia, where Lek d.d.,Novartis Pharma Services Inc. and Sandoz d.d., operate. Together we are building and maintaining the reputation of a dynamic, ethical, and trusted pharmaceutical company. Lek develops, manufactures, and markets effective, safe, and high quality medicines and active pharmaceutical ingredients. With our knowledge, quality, and experience we have gained an important role inNovartis' organizational structure, especially in the Novartis TechnicalOperations, Global Drug Development, Novartis Business Services, and the generic division Sandoz. We are the leading Sandoz development center, and one of the key development sites for technologically complex projects. We invest a great deal in the development, education, and training of our employees.Novartis invested in Slovenia more than EUR 3 billion since 2003.
Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our purpose is to pioneer access for patients by developing and commercializing novel, affordable approaches that address unmet medical needs.Our ambition is to be the world’s leading and most valued generics company. Our broad portfolio of high-quality medicines, covering all major therapeutic areas, accounted for 2021 sales of USD 9.6 billion.
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 108,000 people of more than 140 nationalities work at Novartis around the world. Find out more at www.novartis.com.
This press release contains statements and forecasts of future business operations. The forecasts include estimates based on all theinformation currently available to us. Should these forecasts prove unreliable, the actual results of business operations could be different from those expected.
For further information, please contact:
Communication & External Engagement
Lek Pharmaceuticals d.d.
Telephone: 01 580 22 43